

DRUG UTILIZATION REVIEW BOARD MEETING
January 21, 2009
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Board Members Present

Sandra Bollinger, PharmD
Charlene Heyde, RPh
Stacy Mangum, PharmD
Susan Abdel-Rahman, PharmD
Randy Becker, PharmD
Jennifer Passanise, FNP
Peggy Wanner-Barjenbruch, MD

Board Members Absent:

John Newcomer, MD, Chairman
Joy Gronstedt, DO
David Campbell, M.D.
Joseph Yasso, DO
Sharad Parikh, M.D.

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Tom Beetem, RPh, Infocrossing
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, MD, PharmD, ACS
Bethany Noble, ACS

Others Attending

Jeff Himmelberg, GSK
Pete Rossman, Roche
Debbie King, Amgen
Rob Kilo, Pfizer

Jeff Knappen, Allergan
Susan Zalenski, J and J
Aaron, Mays, Alcon
Alan Garber, Astra Zeneca

Richard Mesquias, Eli Lilly
M. Patty Laster, Genentech
Nancy Wilson, Genzyme
Ann Mattingly, BMS

Kelly Golden, Eli Lilly
Rich Wardrop, Eisai
Todd Houldswurth,

MO HealthNet Division Staff Present:

George L. Oestreich, PharmD, Deputy Director, MHD- Clinical Services
Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Allison Lauf, RN
Mary Heet, RN
Tisha McGowan, Unit Supervisor
DJ Johnson, Medicaid Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jayne Zemmer, Program Manager
Angela Wilson, Medicaid Specialist
Andrew Haslag, Fiscal Manager
Beth McQuaide, Administrative Assistant
Jackie Hickman, Unit Supervisor
Terri Mills, Medicaid Specialist
Julie Trimble, Medicaid Specialist
Kim Morgan,, Correspondence and Information Specialist

*Many names on the sign-in sheet were illegible.. Sign in sheet on file for review.

<p>Welcome, Introductions and Opening Remarks</p>	<p>In the absence of Chairman, John Newcomer, M.D. George L. Oestreich, PharmD, Deputy Division Director called the meeting to order at 10:00 a.m. A quorum was established. A folder of correspondence received and responded to during the quarter, pertaining to the agenda topics, was shared with the Board. A copy of this correspondence is available to Board members upon request. Dr. Oestreich noted that the Governor's State of the State address was scheduled for the following week. He also clarified questions raised at a recent Pharmaceutical Researchers and Manufactures of America (PhRMA) meeting regarding links on the MO HealthNet Web page to prescription assistance sites and verified numbers associated with the managed care plan pharmacy carve out. He also clarified revenue associated with a bill (Representative Sater) currently under discussion in the Legislature regarding psychotropic medications. Dr. Oestreich noted with the recent change in Administration all unconfirmed gubernatorial appointments to boards and commissions had been withdrawn. This did affect the Drug Utilization (DUR) Board which now has one Registered Pharmacist vacancy. MO HealthNet is working on a new Web site page to share advisory group meeting materials and information. MHD will share the page with the Board when completed.</p>
<p>Minutes Approval</p>	<p>Minutes of the October 2008 meeting were reviewed and approved as submitted.</p>
<p>Pharmacy Program/Budget Update</p>	<p>Dr. Oestreich presented Power Point slides entitled "<i>CCIP ASO Outcome Overview</i>". Dr. Oestreich began the presentation with a brief history of the Chronic Care Improvement (CCIP) and Administrative Services Organization (ASO) History. He also discussed coverage by Managed Care Organizations (MCOs) and ASO and fee-for-service coverage for non-MCO participants in MCO regions of the state. Slides summarized desired outcomes and expected impact from CCIP/ASO interventions as well as the engagement process used. Services provided during the engagement process were also discussed. Outcome reports included medical, financial, healthcare home and provider metrics through the second quarter of 2008. Dr. Oestreich summarized where the CCIP patient resides, report methodology and parameters, and provided an overview of the typical participant. Outcomes for diabetes, Chronic Obstructive Pulmonary Disease (COPD) Pharmacy, Congestive Heart Failure (CHF) Pharmacy, Asthma Pharmacy and Coronary Artery Disease (CAD) were shared. The relative cost impact "off trend" was discussed. Slides presented included program eligibility, a trend analysis of total costs, emergency room utilization and costs trend analyses and hospital inpatient utilization and cost analyses. The presentation continued with discussion of the Health and Wellness parameters, enrollees, identified healthcare homes and the primary diseases identified for the non CCIP population. Dr. Oestreich discussed completed assessment totals and approved plans of care. It was noted that the frequency of recommended diagnostic testing and pharmacy utilization was consistently greater for CCIP participants than for non-enrollees. Also when compared to non-enrollees CCIP participants experienced decreased average monthly treatment costs, decreased emergency room utilization, less impatient admissions and an appointment no show rate decrease greater than 50%. Issues and concerns noted included the low number of plan of care approvals, general provider relations, communication and coordination of resources and IT as well as cross validation of data. Dr. Oestreich noted that this data is being validated by the University of Missouri, Columbia. Slides included information regarding the planned ASO for the Southern tier of the state. Dr. Oestreich noted that this project was placed on hold pending proposed budget cuts and did not discuss these slides in detail. Electronic tools in</p>

	use were discussed. Dr. Oestreich summarized each tool's use and how they work together. He detailed current features of CyberAccess, and planned additions to the tool. Direct Inform, the Web portal available for the MO HealthNet participant was discussed while sharing a screen shot of the tool. Questions and comments were taken from the Board and audience throughout the presentation. Copies of slides used are available upon request.
Review of Prior Authorization Meeting:	Copies of the agenda and draft minutes, including public hearing, from the December 18, 2009 <i>Drug Prior Authorization Meeting</i> were included in the members' meeting packet.
Implementation Schedule	An updated copy of the <i>Proposed Implementation Schedule for Edits</i> , including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings, which was the annual review of ½ of the PDL. This schedule may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf
New Drug Review	<ul style="list-style-type: none"> ● Discussion - Drug monographs were available for review at http://www.heritage-info.com/mocaidrx for all new products reviewed this quarter (Identified in July, August and September). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Rhonda.Driver, RPh, Director Pharmacy Program reviewed MHD recommendations. ● Decision – In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote. (See Roll Call Vote)
Clinical Edits:	
SSRI Step Therapy	<ul style="list-style-type: none"> ● Discussion –Edit documents were included in the meeting packet, with proposed changes bolded for easy identification. (See Meeting handout) Jay Bryant-Wimp, RPh, Clinical Pharmacist reviewed the criteria document noting the addition of Sertraline and Paroxetine as additional reference products ● Decision – In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This clinical edit recommendation was included in this vote. (See Roll Call Vote)
Vivitrol	<ul style="list-style-type: none"> ● Discussion –Edit documents were included in the meeting packet, with proposed changes bolded for easy identification. (See Meeting handout) Mr. Bryant-Wimp reviewed the criteria document noting following discussions with the Department of Mental Health (DMH) additional approval criteria had been added to the edit. This criteria will allow for therapy approval for the participant currently enrolled in a CSTAR or other substance abuse program recognized by DMH/Division of Alcohol and Drug Abuse. ● Decision – In the interest of time the Board agreed to block all recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This clinical edit recommendation was included in this vote. (See Roll Call Vote)
Preferred Drug List (PDL)	Products and classes under review this quarter are new to the PDL.

Oral Agents for Ulcerative Colitis	<ul style="list-style-type: none"> • Discussion – Mr. Bryant-Wimp reviewed the criteria document included in the meeting packet. Preferred and non preferred products were reviewed as well as approval and denial criteria. • Decision – This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Rectal Agents for Ulcerative Colitis	<ul style="list-style-type: none"> • Discussion – Mr. Bryant-Wimp reviewed the criteria document including preferred and non-preferred products and approval/denial criteria. • Decision – This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Intravaginal Antibiotics	<ul style="list-style-type: none"> • Discussion – Mr. Bryant-Wimp reviewed the criteria document pointing out approval and denial criteria. • Decision - This PDL recommendation was accepted as presented and added to the block vote. (See Roll Call Votes)
Intranasal Antihistamines	<ul style="list-style-type: none"> • Discussion – Mr. Bryant-Wimp reviewed the criteria document noting preferred and non preferred agents and approval/denial criteria. • Decision - This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)
Preferred Drug List Discussion/Therapeutic Classes	<p>Therapeutic categories to be considered next quarter will be the annual review of products with contracts expiring July 2009. A listing of classes/products under review was provided to all attendees. The Division will also post these classes to the Web page http://www.dss.mo.gov/mhd. Ms. Driver indicated that the Division and First Health Services, Inc. plan to discuss extending some contracts to 18 months to lessen the number of classes at each annual review. This one time extension would allow for the addition of a third quarter to be used for annual review, leaving the 4th quarter for new PDL additions.</p> <p>Ms. Driver and Dr. Oestreich responded to questions from Board members regarding the edit on Skeletal Muscle Relaxants discussed at the last meeting. MHD noted this edit has significantly increased call center volume and will continue to monitor and report back to the group.</p>
Program Statistics:	
Top 25 Drugs by Cost	Top 25 drug lists for the 1 st , 2 nd , 3 rd and 4 th quarters of 2008 were provided for the Boards' information. Copies were available to all attendees.
Clinical Edit Summary Report	An overview report of the clinical edit and prior authorization request transaction counts for the month of December 2007 was provided for all attending. The report detailed total transaction counts as well as information on the outcome (approval or denial) of the request.
Call Center Statistics	A handout illustrating pharmacy help desk call center activity was provided for all attending. Statistics for December 2008 were included. Also included for the Boards' information was a CyberAccess Report. This report detailed statistics for CyberAccess usage from April 2006 through December 2008 and showed how usage has grown overtime. MHD will continue to provide this information if the Board finds it interesting and useful. Ms. Driver asked members to provide suggestions for other statistical information they would like presented.
Program Utilization Information	A copy of the FFS Cough and Cold Covered Products List was provided to Members and all attendees. Ms. Driver noted that the list had been updated following recent Food and Drug Administration (FDA) recommendations and several products had been removed. The Division is considering additional criteria to be used for the coverage of these products for the very young child, which might include messaging to the

	provider or blocking children from adult formulations. This information will be shared with the group at a later date.
ACS Healthcare Update	<p>Jennifer Kemp-Cornelius, PharmD. ACS Healthcare Systems provided each member with a copy of the current Tramadol Clinical Edit Criteria Document. She also provided a handout detailing utilization including claim volume for 2003 through 2008, as well as paid amounts for 2008. Information on how many times the edit was hit, call center approvals vs. denials and the reason for denial was also presented for the Boards' consideration. Clinical and step therapy edits are not reviewed annually as are PDL edits and Dr. Kemp-Cornelius plans to bring these types of edits to the advisory groups attention from time to time if they feel it is beneficial. Members were urged to contact her if there was additional information they would like made available.</p> <p>Dr. Kemp-Cornelius stated the Division is working on upgrades to provide data that will provide access to more information which will allow for more targeted involvement over the current DUR intervention mailings and give the DUR member the opportunity for more involvement..</p>
Adjourn	<p>Dr. Oestreich updated the group on the progress of the new pharmacy provider tax including cost savings to the state. Ms. Driver announced the carve out of pharmacy from all Managed Care Health Plans with the new contracts effective October 2009. This will allow for one pharmacy benefit for all participants across the state. The next meeting is scheduled for April 15, 2009. The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote)</p>

Roll Call Votes – January 21, 2009

Member	<i>New Drug And Clinical Edits</i>	PDL Edits	Closed Session	<i>Adjourn</i>
Susan Abdel-Rahman	<i>Motion</i>	Motion	Yeah	Yeah
Randy Beckner	Yeah	<i>Yeah</i>	<i>Yeah</i>	<i>Yeah</i>
Sandra Bollinger	Yeah	Yeah	Yeah	<i>Second</i>
Jennifer Passanise	Yeah	Yeah	Motion	Yeah
David Campbell	<i>Absent</i>	Absent	Absent	Absent
Joy S. Gronstedt	<i>Absent</i>	Absent	Absent	Absent
Stacy Mangum	<i>Second</i>	Yeah	Yeah	Motion
John Newcomer	<i>Absent</i>	Absent	Absent	Absent
Sharad Parikh	Absent	Absent	Absent	Absent
Charlene Heyde	Yeah	<i>Yeah</i>	Yeah	Yeah
Peggy Wanner- Barjenbruch	Yeah	Second	Second	Yeah
Joseph M. Yasso	Absent	Absent	<i>Absent</i>	<i>Absent</i>

EXECUTIVE SESSION

January 21, 2009

Board Members Present

Sandra Bollinger, PharmD
Charlene Heyde, RPh
Stacy Mangum, PharmD
Susan Abdel-Rahman, PharmD
Randy Becker, PharmD
Jennifer Passanise, FNP
Peggy Wanner-Barjenbruch, MD

Board Members Absent:

John Newcomer, MD, Chairman
Joy Gronstedt, DO
David Campbell, M.D.
Joseph Yasso, DO
Sharad Parikh, M.D.

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Tom Beetem, RPh, Infocrossing
Jennifer Kemp-Cornelius, PharmD, ACS
Mark Roaseau, MD, PharmD, ACS
Bethany Noble, ACS

MO HealthNet Division Staff Present:

George L. Oestreich, PharmD, Deputy Director, MHD- Clinical Services
Rhonda Driver, RPh, Director Pharmacy Program
Jay Bryant-Wimp, RPh, Clinical Pharmacist
Allison Lauf, RN
Mary Heet, RN
Tisha McGowan, Unit Supervisor
DJ Johnson, Medicaid Specialist
Lisa Clements, PhD, Clinical Director Psychology Program
Jayne Zemmer, Program Manager
Angela Wilson, Medicaid Specialist
Andrew Haslag, Fiscal Manager
Beth McQuaide, Administrative Assistant
Jackie Hickman, Unit Supervisor
Terri Mills, Medicaid Specialist
Julie Trimble, Medicaid Specialist
Kim Morgan,, Correspondence and Information Specialist

EXECUTIVE SESSION	
Minutes Review	Minutes of the October Executive Session were approved as submitted
Case Reviews	Ms. Driver and Mr. Bryant Wimp presented the case of a 40 year old female presenting with non-cancer/terminal illness pain. Her medications include generic Actiq 1600 mcg q4h, fetanyl patch 100 mcg/hr q48h and various other oral pain medications.. History notes frequent early refill requests, numerous reports of medication thefts and multiple discrepancies in medication counts between on hand medications and physician calculations. MHD current plan is for evaluation for implantation of a neurostimulator. The Board was asked for suggestions regarding evidence-based medicine for pain control and for weaning Actiq in light of the black box warning. Suggestions were discussed, including blood levels and tapering down of her dose. Most members agreed this participant is in need of extensive rehabilitation services.
Adjourn	Executive session adjourned. (See role call vote)